62.25

0.48% 0.30

After Hours: 62.24 -0.010 -0.02%

Rhythm Pharmaceuticals Inc (RYTM)

Overview News Price History Option Chain Financials Discussions Forecast

Rhythm Pharmaceuticals Inc stock is traded at $62.25, with a volume of 421.64K. It is up +0.48% in the last 24 hours and up +28.22% over the past month. Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

Previous Close:

$61.95

Open:

$62.24

24h Volume:

421.64K

Relative Volume:

0.95

Market Cap:

$3.80B

Revenue:

$101.78M

Net Income/Loss:

$-259.43M

P/E Ratio:

-18.98

EPS:

-3.28

Net Cash Flow:

$-163.06M

1W Performance:

+4.87%

1M Performance:

+28.22%

6M Performance:

+69.34%

1Y Performance:

+82.87%

1-Day Range:

$61.55

$63.44

1-Week Range:

$57.99

$63.44

52-Week Range:

$31.52

$68.58

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name

Rhythm Pharmaceuticals Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

857-264-4280

Address

222 BERKELEY STREET, BOSTON, MA

Employee

226

Twitter

@rhythmpharma

Next Earnings Date

2024-11-05

Latest SEC Filings

RYTM's Discussions on Twitter

Compare RYTM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RYTM Rhythm Pharmaceuticals Inc	62.25	3.80B	101.78M	-259.43M	-163.06M	-3.28
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-24	Initiated	Guggenheim	Buy
Sep-18-24	Initiated	H.C. Wainwright	Buy
Sep-17-24	Initiated	JMP Securities	Mkt Outperform
May-08-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy
Jan-18-23	Resumed	Canaccord Genuity	Buy
Aug-08-22	Upgrade	Goldman	Neutral → Buy
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-22	Reiterated	Needham	Buy
Mar-02-22	Resumed	Stifel	Buy
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-14-21	Resumed	Goldman	Neutral
Aug-04-21	Downgrade	BofA Securities	Neutral → Underperform
Aug-04-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Nov-30-20	Downgrade	BofA Securities	Buy → Neutral
Jan-08-20	Initiated	Goldman	Sell
Jul-12-19	Upgrade	Stifel	Hold → Buy
Jul-08-19	Initiated	Canaccord Genuity	Buy
Mar-13-19	Initiated	Ladenburg Thalmann	Buy
Sep-07-18	Resumed	Morgan Stanley	Overweight
Jun-25-18	Reiterated	Needham	Buy
Jun-15-18	Reiterated	Needham	Buy
Oct-30-17	Initiated	BofA/Merrill	Buy
Oct-30-17	Initiated	Needham	Buy

View All

Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News

Nov 27, 2024

Healthcare of Ontario Pension Plan Trust Fund Purchases 143,800 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat

Nov 27, 2024

Algert Global LLC Decreases Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat

Nov 27, 2024

Penserra Capital Management LLC Makes New $1.31 Million Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat

Nov 27, 2024

Nov 26, 2024

Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve

Nov 26, 2024

Loomis Sayles & Co. L P Invests $33.35 Million in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat

Nov 26, 2024

Nov 25, 2024

Where are the Opportunities in (RYTM) - Stock Traders Daily

Nov 25, 2024

Rhythm Pharmaceuticals retains stock target, buy rating on new data By Investing.com - Investing.com Canada

Nov 25, 2024

Rhythm Pharmaceuticals (NASDAQ:RYTM) Given Buy Rating at HC Wainwright - MarketBeat

Nov 25, 2024

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts - Inkl

Nov 25, 2024

Nov 24, 2024

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Nov 24, 2024

Nov 23, 2024

Principal Financial Group Inc. Increases Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat

Nov 23, 2024

Nov 22, 2024

Rhythm Pharmaceuticals Provides Information to the Shareholders - Marketscreener.com

Nov 22, 2024

Nov 21, 2024

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Primecap Management Co. CA - MarketBeat

Nov 21, 2024

Nov 18, 2024

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide - GlobeNewswire

Nov 18, 2024

Rhythm Pharma: New Drug Shows 9.6% Weight Loss in Pediatric Obesity Treatment Study | RYTM Stock News - StockTitan

Nov 18, 2024

Nov 15, 2024

Perceptive Advisors LLC's Strategic Acquisition in Rhythm Pharma - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

(RYTM) Proactive Strategies - Stock Traders Daily

Nov 14, 2024

Rhythm pharmaceuticals CTO Joseph Shulman sells $882,340 in stock By Investing.com - Investing.com Nigeria

Nov 14, 2024

Rhythm Pharmaceuticals EVP sells $4.43m in stock By Investing.com - Investing.com UK

Nov 14, 2024

Nov 13, 2024

Rhythm pharmaceuticals CTO Joseph Shulman sells $882,340 in stock - Investing.com

Nov 13, 2024

Rhythm Pharmaceuticals EVP sells $4.43m in stock - Investing.com

Nov 13, 2024

Rhythm Pharmaceuticals Announces Publication of Results - GlobeNewswire

Nov 13, 2024

Rhythm Pharma's Obesity Drug Shows 83% Success in Phase 3 Trial, FDA Priority Review Set | RYTM Stock News - StockTitan

Nov 13, 2024

Rhythm Pharmaceuticals Announces New Employment Inducement Grants - GlobeNewswire

Nov 13, 2024

Rhythm Pharmaceuticals Awards 15,750 RSUs to New Employees in Talent Acquisition Push | RYTM Stock News - StockTitan

Nov 13, 2024

PRIMECAP Management Adjusts Stake in Rhythm Pharmaceuticals - GuruFocus.com

Nov 13, 2024

Goldman Sachs Group Inc Reduces Stake in Rhythm Pharmaceuticals Inc - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

High Growth Tech Stocks Featuring Three Prominent US Companies - Simply Wall St

Nov 12, 2024

Nov 11, 2024

Rhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 52-Week HighWhat's Next? - MarketBeat

Nov 11, 2024

HC Wainwright Issues Pessimistic Outlook for RYTM Earnings - MarketBeat

Nov 11, 2024

Nov 09, 2024

Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $585,940 in stock By Investing.com - Investing.com Australia

Nov 09, 2024

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 4,688 Shares of Stock - MarketBeat

Nov 09, 2024

Nov 08, 2024

Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $585,940 in stock - Investing.com

Nov 08, 2024

Nov 07, 2024

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $69.00 - MarketBeat

Nov 07, 2024

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024

Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 07, 2024